Why the study?
Does enoxaparin reduce death and non-fatal myocardial infarction compared to unfractionated heparin in STEMI patients receiving fibrinolytic therapy?
Does enoxaparin reduce death and non-fatal myocardial infarction compared to unfractionated heparin in STEMI patients receiving fibrinolytic therapy?
No takes yet. Share an insight, caveat, or question.
Enoxaparin provides a significant reduction in death and non-fatal MI compared to UFH in STEMI patients treated with fibrinolysis, leading to an FDA-approved indication.
Giraldez et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: